Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor overview
Stock information
Press releases
Events
SEC filings
Corporate governance
Investor presentations
Investor FAQs
Email alerts

Investor contact

For investor related questions, please email

investors@aclaristx.com

Media contact
& resources »

Press Releases

Press Releases

Year

March 18, 2019

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

March 8, 2019

Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019

February 28, 2019

Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg

February 19, 2019

Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology

January 2, 2019

Aclaris Therapeutics to Attend Upcoming Investor Conferences

Aclaris - Footer Menu

Terms of use
Privacy policy
Media resources
Contact us

© 2019 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.